The prognostic significance of p16 expression pattern in diffuse gliomas

Area of Science:

• Neuro-oncology
• Cancer genetics
• Tumor suppressor genes

Background:

• CDKN2A gene loss is linked to poor survival in IDH-mutant gliomas.
• p16 protein is encoded by the CDKN2A gene and acts as a cell cycle inhibitor.
• Assessing p16 immunohistochemistry as a prognostic marker is crucial for diffuse gliomas.

Purpose of the Study:

• To analyze the prognostic value of p16 expression in diffuse gliomas.
• To determine if p16 immunohistochemistry can replace CDKN2A genotyping for prognosis.
• To investigate the correlation between p16 expression levels and patient survival.

Main Methods:

• p16 immunohistochemistry performed on 326 diffuse gliomas.
• Gliomas classified by IDH-mutation and 1p/19q codeletion status.
• Survival analysis conducted based on p16 expression levels (negative, focal, overexpression).

Main Results:

• Loss of p16 expression significantly correlated with worse outcomes in all gliomas (p<.001) and IDH-mutant gliomas (p=.010).
• p16 loss was a significant predictor in IDH-mutant astrocytomas (p=.032) but not in IDH-wildtype gliomas (p=.121).
• p16 overexpression also associated with shorter survival in gliomas (p<.001) and IDH-mutant gliomas (p=.046).

Conclusions:

• p16 immunohistochemistry is a valuable surrogate marker for predicting prognosis in diffuse gliomas.
• This method is particularly useful for IDH-mutant astrocytoma patients.
• p16 staining offers a practical alternative to CDKN2A genotyping for prognostic assessment.